These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cannabis-based medicines for chronic neuropathic pain in adults. Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392 [TBL] [Abstract][Full Text] [Related]
23. Advancing the science on cannabis concentrates and behavioural health. Bidwell LC; Martin-Willett R; Karoly HC Drug Alcohol Rev; 2021 Sep; 40(6):900-913. PubMed ID: 33783029 [TBL] [Abstract][Full Text] [Related]
24. Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes. Morean ME; Lederman IR Addict Behav; 2019 Jun; 93():233-239. PubMed ID: 30772776 [TBL] [Abstract][Full Text] [Related]
25. 'Synthetic cannabis': A dangerous misnomer. Darke S; Banister S; Farrell M; Duflou J; Lappin J Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944 [TBL] [Abstract][Full Text] [Related]
26. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study. Kayser RR; Haney M; Raskin M; Arout C; Simpson HB Depress Anxiety; 2020 Aug; 37(8):801-811. PubMed ID: 32383271 [TBL] [Abstract][Full Text] [Related]
27. Chemical profiling of Cannabis varieties cultivated for medical purposes in southeastern Brazil. Carvalho VM; de Almeida FG; de Macêdo Vieira AC; Rocha ED; Cabral LM; Strongin RM Forensic Sci Int; 2022 Jun; 335():111309. PubMed ID: 35462181 [TBL] [Abstract][Full Text] [Related]
28. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Rice J; Cameron M Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025 [TBL] [Abstract][Full Text] [Related]
29. Cannabinoid Profiles in Medical Cannabis Users: Effects of Age, Gender, Symptoms, and Duration of Use. Kalaba M; Ware MA Cannabis Cannabinoid Res; 2022 Dec; 7(6):840-851. PubMed ID: 33999649 [No Abstract] [Full Text] [Related]
30. Clinical uses of cannabis and cannabinoids in the United States. Levinsohn EA; Hill KP J Neurol Sci; 2020 Apr; 411():116717. PubMed ID: 32044684 [TBL] [Abstract][Full Text] [Related]
31. Medical cannabis use in Thailand after its legalization: a respondent-driven sample survey. Assanangkornchai S; Thaikla K; Talek M; Saingam D PeerJ; 2022; 10():e12809. PubMed ID: 35047242 [TBL] [Abstract][Full Text] [Related]
32. Adult use of highly-potent Δ9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021. Hasin DS; Borodovsky J; Shmulewitz D; Walsh C; Struble CA; Livne O; Habib MI; Fink DS; Aharonovich E; Budney A Addict Behav; 2023 May; 140():107617. PubMed ID: 36736229 [TBL] [Abstract][Full Text] [Related]
33. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC. Lile JA; Kelly TH; Hays LR Drug Alcohol Depend; 2011 Jul; 116(1-3):86-92. PubMed ID: 21227600 [TBL] [Abstract][Full Text] [Related]
34. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. Baron EP Headache; 2015 Jun; 55(6):885-916. PubMed ID: 26015168 [TBL] [Abstract][Full Text] [Related]
35. Sex Differences in Plasma, Adipose Tissue, and Central Accumulation of Cannabinoids, and Behavioral Effects of Oral Cannabis Consumption in Male and Female C57BL/6 Mice. Sallam NA; Peterson CS; Baglot SL; Kohro Y; Trang T; Hill MN; Borgland SL Int J Neuropsychopharmacol; 2023 Nov; 26(11):773-783. PubMed ID: 37715955 [TBL] [Abstract][Full Text] [Related]
36. Cannabinoids: Medical implications. Schrot RJ; Hubbard JR Ann Med; 2016; 48(3):128-41. PubMed ID: 26912385 [TBL] [Abstract][Full Text] [Related]
37. A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products. Nutt DJ; Phillips LD; Barnes MP; Brander B; Curran HV; Fayaz A; Finn DP; Horsted T; Moltke J; Sakal C; Sharon H; O'Sullivan SE; Williams T; Zorn G; Schlag AK Cannabis Cannabinoid Res; 2022 Aug; 7(4):482-500. PubMed ID: 33998895 [No Abstract] [Full Text] [Related]
38. Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ Wurz GT; Montoya E; DeGregorio MW J Cannabis Res; 2022 Jul; 4(1):36. PubMed ID: 35799289 [TBL] [Abstract][Full Text] [Related]
39. Copycat and lookalike edible cannabis product packaging in the United States. Ompad DC; Snyder KM; Sandh S; Hagen D; Collier KJ; Goldmann E; Goodman MS; Tan ASL Drug Alcohol Depend; 2022 Jun; 235():109409. PubMed ID: 35459519 [TBL] [Abstract][Full Text] [Related]
40. Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019. Klein TA; Dilley JA; Graves JM; Liebelt EL Clin Toxicol (Phila); 2022 Sep; 60(9):1024-1028. PubMed ID: 35942512 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]